ABSTRACT
Fibrotic-like abnormalities are present in 60% of a single-center, longitudinal, multi-ethnic cohort 3-years after severe COVID-19. They are independently associated with male sex, low BMI, shorter telomere length, increased severity of illness, and mechanical ventilation; Black race and asthma are protective. Participants with fibrotic-like abnormalities are more likely to have reduced diffusion capacity and 6-minute walk distance. Fibrotic-like abnormalities persist but modestly improve over time. Transbronchial biopsies show small airways histopathology, consistent with high prevalence of air trapping in expiration, and infrequent interstitial thickening. This study highlights the need for continued monitoring of patients with persistent fibrosis after severe COVID-19.
Competing Interest Statement
CMcG reports relationship with Boehringer Ingelheim outside the scope of this study. MS reports relationships with Boehringer Ingelheim, Genentech, Bioclinica, AbbVie, Lunglife AI, the France Foundation, and Peer View outside the scope of this study. KMC reports relationships with Cardinal Health and Guidepoint outside the scope of this study. AS reports relationships with Boehringer Ingelheim, Genentech, Gilead, AbbVie, and Veracyte outside the scope of this study. CKG reports a relationship with Rejuvenation Technologies, Inc. and Boehringer Ingelheim outside the scope of this study.
Funding Statement
This work was supported by the NIH (T32HL105323 to SOM; UL1TR001873 to MRB; R01HL093096 to CKG) and the Department of Defense (PR202907 to CKG and MRB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Protection Office/Institutional Review Board of Columbia University IRB 5 gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Statement: This work was supported by the NIH (T32HL105323 to SOM; UL1TR001873 to MRB; R01HL093096 to CKG) and the Department of Defense (PR202907 to CKG and MRB).
Competing Interests: CMcG reports relationship with Boehringer Ingelheim outside the scope of this study. MS reports relationships with Boehringer Ingelheim, Genentech, Bioclinica, AbbVie, Lunglife AI, the France Foundation, and Peer View outside the scope of this study. KMC reports relationships with Cardinal Health and Guidepoint outside the scope of this study. AS reports relationships with Boehringer Ingelheim, Genentech, Gilead, AbbVie, and Veracyte outside the scope of this study. CKG reports a relationship with Rejuvenation Technologies, Inc. and Boehringer Ingelheim outside the scope of this study.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
